Roundup: Indonesian digital pharmacy Lifepack raises $7M in Series A funding and more briefs


Indonesian digital pharmacy Lifepack scores $7M in Series A funding

Lifepack, a digital pharmacy in Indonesia, has raised $7 million in a Series A funding round led by Golden Gate Ventures. 

Launched in 2020, the mobile health platform offers quality and cheap medicines, including over-the-counter drugs, general supplements, and medication for chronic illnesses. Available on Android and iOS devices, Lifepack also provides on-demand online consultation from registered doctors and a team of certified pharmacists. 

According to a news report, its fresh funds will go to building seven more pharmacy warehouses across Indonesia, adding to its existing two warehouses in Jakarta and Surabaya.

CureApp signs license deal with Sawai Group for upcoming NASH DTx app

Japanese medical technology company CureApp is getting an investment worth up to 10.5 billion yen ($77 million) as part of a newly signed deal with the pharmaceutical firm Sawai Group. 

The license agreement will provide the Sawai Group exclusive rights for the development and marketing of a new digital therapeutics app for the treatment of non-alcoholic steatohepatitis (NASH), an advanced form of non-alcoholic fatty liver disease. 

CureApp notes that there are some two million patients with NASH in Japan today with 10 million more who are at risk of developing the disease. 

Its upcoming DTx app will provide users with a personalised daily behaviour therapy regimen and a visual guide of their treatment status. 

The company plans to roll out the app in medical institutions via its proprietary app prescription service. Presently, CureApp is preparing to enter the third phase of clinical trials of the NASH DTx app. 

Wipro GE Healthcare ties up with Boston Scientific for combined heart care offerings in India

Medical technology company Wipro GE Healthcare and Boston Scientific, a US-based medical device manufacturer, have entered into a collaboration to deliver end-to-end interventional cardiac care solutions in India. 

Boston Scientific will combine its medical devices with GE Healthcare’s medical imaging systems, particularly its cardiac catheterisation lab and related software, to support diagnostics through treatment and monitoring of the cardiac patient-care pathway.

The organisations will also support the training and education of healthcare professionals and will raise consumer awareness about the innovations in cardiac catheterisation procedures.

A similar collaboration that offers their combined cardiology solutions has also kicked off in Southeast Asia.

Mental health app Intellect supports Banyan Tree’s wellness programme

Digital mental health platform Intellect has partnered with multinational hospitality group Banyan Tree to support the latter’s wellbeing programme. 

Guests who have booked the Wellbeing Sanctuary service at Banyan Tree Bintan in Indonesia will have access to the Intellect mobile app as part of an end-to-end wellbeing support package.

From August, guided content and habit-building programs from the Intellect app will be made available for guests to access throughout and after their stay.

AstraZeneca to deliver Alveofit’s IoT-powered spirometers across Indian care settings 

AstraZeneca India has teamed up with digital respiratory care platform Alveofit to deliver IoT-enabled spirometers across its network of care settings in India.

According to a press statement, the Alveofit devices will be used to remotely monitor the conditions of patients with lung disorders and associated non-communicable diseases like asthma, pulmonary fibrosis and chronic obstructive pulmonary disease.

It will be distributed in select hospitals under AstraZeneca’s A.Catalyst network, which includes Employee’s State Insurance Corp. hospitals, command and military hospitals, general hospitals and last mile clinics in cities such as Lucknow, Chennai, Nagpur, Delhi, Ahmedabad and Kolkata.


Source link

Recommended Posts

No comment yet, add your voice below!

Add a Comment